Teva Pharmaceutical Issues €1.5B and $3.2B Senior Notes

What Happened
Teva Pharmaceutical Industries Ltd. announced on September 16, 2026 that three of its wholly owned finance subsidiaries issued multiple series of senior unsecured notes totaling €1.5 billion and $3.2 billion. The offerings include: €1,000,000,000 4.250% notes due 2033 and €500,000,000 4.625% notes due 2036; $1,200,000,000 5.250% notes due 2032, $1,000,000,000 5.500% notes due 2034 and $1,000,000,000 5.750% notes due 2037. The notes are guaranteed on a senior unsecured basis by Teva Pharmaceutical Industries Limited.

Key Details

• Issuance date: September 16, 2026; issuers: Teva Pharmaceutical Finance Netherlands II / III / IV B.V.; trustee: The Bank of New York Mellon.
• Interest/payment: Euro notes — annual interest (March 16 or September 16); USD notes — semiannual interest payable Jan 16 and July 16 beginning Jan 16, 2027.
• Use of proceeds: to fund conditional redemptions of several outstanding Teva notes, pay related fees/expenses and for general corporate purposes; proceeds may be temporarily invested.
• Conditional redemptions (notices issued Sept 8 and Sept 10, 2026) target several existing series, including all of the 2028, 2029 and 2031 sustainability‑linked notes and up to specified amounts of 2027 and 2030 series.
• Key covenant/terms: notes are senior unsecured, guaranteed by the parent; indentures include customary covenants (limits on liens and sale‑leasebacks), a change‑of‑control repurchase at 101% of principal plus accrued interest, and standard events of default.

Why It Matters
This filing shows Teva raising long‑dated debt at fixed rates to refinance and restructure upcoming maturities and fund corporate needs. For investors, the new notes change the company’s debt maturity profile (extending weighted maturities) and replace higher‑coupon legacy securities via conditional redemptions. The obligations are unsecured but guaranteed by the parent; the indentures include typical protections (e.g., change‑of‑control repurchase). Monitor future redemption confirmations and how proceeds are applied, since those actions affect Teva’s interest expense and near‑term liquidity.